Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
521 | 14318 | 46.4 | 90% |
Classes in level above (level 3) |
Classes in level below (level 1) |
ID, lev. below | Publications | Label for level below |
---|---|---|
2301 | 2220 | E2F//P107//P130 |
3485 | 1894 | CYCLIN D1//CYCLIN E//CCND1 |
3711 | 1847 | P14ARF//P16//P16INK4A |
3974 | 1795 | CAK//CDC2//CYCLIN A1 |
5202 | 1589 | SKP2//P27KIP1//P27 |
6779 | 1368 | FLAVOPIRIDOL//CELL CYCLE REGULAT GRP//ROSCOVITINE |
8348 | 1193 | P21//P21WAF1 CIP1//WAF1 |
11814 | 888 | CDK5//P35//CYCLIN DEPENDENT KINASE 5 |
13986 | 736 | PEDIAT CHILDREN SURG//SOMATIC GENOME VARIATIONS//HUMAN PERIPHERAL CELLS |
24786 | 252 | UCN 01//7 HYDROXYSTAUROSPORINE//7 HYDROXYSTAUROSPORINE UCN 01 |
25390 | 235 | CCNG2//CYCLIN G2//CYCLIN G |
27801 | 181 | ARID3B//JUMONJI//AT RICH INTERACTION DOMAIN |
31665 | 120 | GANKYRIN//P28GANK//PSMD10 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CELL CYCLE | Author keyword | 212 | 11% | 13% | 1801 |
2 | CDK5 | Author keyword | 206 | 56% | 2% | 250 |
3 | E2F | Author keyword | 200 | 49% | 2% | 300 |
4 | CYCLIN D1 | Author keyword | 174 | 26% | 4% | 574 |
5 | P27 | Author keyword | 154 | 36% | 2% | 345 |
6 | CYCLIN DEPENDENT KINASE | Author keyword | 152 | 40% | 2% | 297 |
7 | SKP2 | Author keyword | 145 | 63% | 1% | 145 |
8 | P27KIP1 | Author keyword | 144 | 37% | 2% | 309 |
9 | FLAVOPIRIDOL | Author keyword | 125 | 63% | 1% | 126 |
10 | CDK | Author keyword | 103 | 39% | 1% | 205 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CELL CYCLE | 212 | 11% | 13% | 1801 | Search CELL+CYCLE | Search CELL+CYCLE |
2 | CDK5 | 206 | 56% | 2% | 250 | Search CDK5 | Search CDK5 |
3 | E2F | 200 | 49% | 2% | 300 | Search E2F | Search E2F |
4 | CYCLIN D1 | 174 | 26% | 4% | 574 | Search CYCLIN+D1 | Search CYCLIN+D1 |
5 | P27 | 154 | 36% | 2% | 345 | Search P27 | Search P27 |
6 | CYCLIN DEPENDENT KINASE | 152 | 40% | 2% | 297 | Search CYCLIN+DEPENDENT+KINASE | Search CYCLIN+DEPENDENT+KINASE |
7 | SKP2 | 145 | 63% | 1% | 145 | Search SKP2 | Search SKP2 |
8 | P27KIP1 | 144 | 37% | 2% | 309 | Search P27KIP1 | Search P27KIP1 |
9 | FLAVOPIRIDOL | 125 | 63% | 1% | 126 | Search FLAVOPIRIDOL | Search FLAVOPIRIDOL |
10 | CDK | 103 | 39% | 1% | 205 | Search CDK | Search CDK |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RETINOBLASTOMA PROTEIN | 513 | 32% | 9% | 1348 |
2 | DEPENDENT KINASE INHIBITOR | 472 | 41% | 6% | 901 |
3 | P27 | 305 | 57% | 3% | 360 |
4 | S PHASE ENTRY | 287 | 59% | 2% | 324 |
5 | CDK INHIBITORS | 281 | 42% | 4% | 520 |
6 | P27KIP1 | 280 | 34% | 5% | 675 |
7 | DEPENDENT KINASES | 273 | 38% | 4% | 576 |
8 | CYCLIN DEPENDENT KINASES | 229 | 27% | 5% | 723 |
9 | CELL CYCLE | 212 | 10% | 14% | 1965 |
10 | CYCLIN DEPENDENT KINASE 5 | 206 | 41% | 3% | 395 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CELL DIVISION | 3 | 13% | 0% | 24 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The history and future of targeting cyclin-dependent kinases in cancer therapy | 2015 | 11 | 176 | 68% |
Cyclin D as a therapeutic target in cancer | 2011 | 254 | 182 | 66% |
Cancer cell cycles | 1996 | 3982 | 180 | 69% |
Cell cycle, CDKs and cancer: a changing paradigm | 2009 | 832 | 164 | 35% |
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy | 2008 | 387 | 198 | 71% |
p21 in cancer: intricate networks and multiple activities | 2009 | 602 | 223 | 47% |
Cyclin-dependent kinase pathways as targets for cancer treatment | 2006 | 455 | 185 | 79% |
Molecular mechanisms underlying RB protein function | 2013 | 67 | 89 | 76% |
The regulation of E2F by pRB-family proteins | 1998 | 1610 | 183 | 89% |
CDK inhibitors: Cell cycle regulators and beyond | 2008 | 397 | 133 | 60% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CELL CYCLE REGULAT GRP | 37 | 67% | 0.2% | 34 |
2 | DTP CLIN TRIALS UNIT | 15 | 88% | 0.0% | 7 |
3 | MOLEC BIOL MB7 | 14 | 100% | 0.0% | 7 |
4 | MOL THER EUT UNIT | 13 | 58% | 0.1% | 15 |
5 | HOTEL RECH | 12 | 86% | 0.0% | 6 |
6 | PERINATOGYNECOL | 11 | 69% | 0.1% | 9 |
7 | TUMOR CELL BIOL | 9 | 11% | 0.6% | 82 |
8 | SBARRO CANC MOL MED | 9 | 13% | 0.4% | 64 |
9 | PEDIAT CHILDREN SURG | 7 | 56% | 0.1% | 9 |
10 | GENET CANC GRP | 6 | 80% | 0.0% | 4 |
Related classes at same level (level 2) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000023865 | RETINOBLASTOMA//CHEMOREDUCTION//OPHTHALM ONCOL SERV |
2 | 0.0000018057 | P73//MDM2//P53 |
3 | 0.0000012232 | ASTROCYTE ELEVATED GENE 1//AEG 1//DREF |
4 | 0.0000011144 | ID 1//NRSF//MYC |
5 | 0.0000010094 | GEMININ//DNA REPLICATION//CDC6 |
6 | 0.0000009608 | E1A//BIOL MOL ELADIO VINUELA//PHAGE PHI 29 |
7 | 0.0000008903 | MIDBLASTULA TRANSITION//FROG OOCYTE//GLYCOGEN BODY |
8 | 0.0000007580 | ARECA NUT//ORAL SUBMUCOUS FIBROSIS//ORAL CANCER |
9 | 0.0000007513 | KINETOCHORE//MITOSIS//CENTROSOME |
10 | 0.0000007276 | PROTEASOME//UBIQUITIN//NEDD8 |